Day: October 11, 2024

Approval is based on Phase III INAVO120 results, showing the Itovebi™ (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting1 This approval helps address an urgent unmet need in breast cancer for people with a PIK3CA mutation, one of the most commonly mutated genes in HR-positive disease, associated with poor prognosis2,3 Itovebi is Roche’s first targeted therapy approved for people with HR-positive disease, the most prevalent breast cancer subtype, marking an important step in our ambition to continue bringing innovative medicines to more people with breast cancer4,5         Basel, 11 October 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States Food and Drug Administration (FDA) approved Itovebi™...

GUANGZHOU, China, Oct. 10, 2024 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), an innovative company in the field of precision oncology, and Dizal, a global biopharmaceutical company focused on malignant tumors and immunological diseases, jointly announced that the companion diagnostic (CDx) for EGFR exon 20 insertion mutation (exon20ins) for sunvozertinib, developed through their collaboration, has been approved by the National Medical Products Administration (NMPA) of China. This marks the first co-developed NGS-based CDx for lung cancer approved by NMPA since the release of the CDx guideline in China. The approval of this CDx test is the result of the simultaneous development of Burning Rock’s independently developed LungCure CDx (a kit for the combined detection of 9 human...

VANCOUVER, British Columbia, Oct. 10, 2024 (GLOBE NEWSWIRE) — Mustang Energy Corp. (CSE: MEC)(the “Company” or “Mustang”) is pleased to announce the acquisition of 45,585 hectares of prospective land across the Southern and Western Athabasca Basin in Saskatchewan. This expansion was achieved through a combination of low-cost staking and a strategic purchase agreements, as previously announced in the Company’s news release dated September 9, 2024 and September 26, 2024. The newly acquired properties include the Yellowstone Project (21,820 hectares – see Figure 2), the Dutton Project (9,666 hectares – see Figure 3), and three additional claims (14,098 hectares) which are currently unnamed. With these acquisitions, Mustang’s total land holdings in the Athabasca Basin have increased from 10,644 hectares—comprising the Ford Lake, Cigar...

Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of its previously announced underwritten public offering of 16,250,000 ordinary shares at a public offering price of $9.25 per share. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be approximately $150 million. The offering is expected to close on October 15, 2024, subject to customary closing conditions. In addition, Immatics has granted the underwriters a 30-day option to purchase up to 2,437,500 additional shares at the public offering price, less the underwriting discount. Jefferies, BofA Securities and Leerink...